Depomed Receives $5 Million Milestone Payment for Delivery of Formulation (Depomed press release); Depomed had developed four prototype formulations and one of them meets required specifications. This is development towards fixed dose combination of canagliflozin and metformin ER. Note: Depomed is already marketing Metformin ER (Glumetza) alone formulation.
Sandoz Vs Boehringer
Sandoz filed a complaint for declaratory judgement on patent non-infringement against Boehringer. Sandoz filed a ANDA for Epinastine Ophthalmic solution which was marketed by Allergen. US patent 7429602 is assigned to Boehringer and listed in OB for Epinastine Hcl. Boehringer has not sued sandoz after the receipt of ANDA notice, rather boehringer has disclaimed all the claims of ‘602 patent and delisting flag request also appears in OB. Sandoz now prays for declaratory judgement for patent non-infringement or invalidity. (Complaint)
Warner Chilcott Announces FDA Approval of New Oral Contraceptive (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) (Press Release)
Shionogi settles patent infringement lawsuit against Sawai and Itochu for crystal patent of Flomox (Cefcapene pivoxil) at the intellectual property high court. Patent No JP2960790 Expiry: Mar 2011 (Press release)
CHMP Novartis’s Lucentis® (ranibizumab) is recommended for Diabetic Macular Edema in EU (Press release)